Corresponding Author: Michael Cohen-Wolkowiez, MD, PhD, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27705 (email@example.com).
Accepted for Publication: May 13, 2020.
Published Online: June 5, 2020. doi:10.1001/jamapediatrics.2020.2422
Author Contributions: Dr Cohen-Wolkowiez had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Maharaj, C. P. Hornik, Balevic, Smith, Benjamin, Cohen-Wolkowiez.
Acquisition, analysis, or interpretation of data: Maharaj, Wu, C. P. Hornik, Balevic, C. D. Hornik, Gonzalez, Zimmerman, Cohen-Wolkowiez.
Drafting of the manuscript: Maharaj, Wu, C. P. Hornik, C. D. Hornik.
Critical revision of the manuscript for important intellectual content: Maharaj, C. P. Hornik, Balevic, C. D. Hornik, Smith, Gonzalez, Zimmerman, Benjamin, Cohen-Wolkowiez.
Statistical analysis: Maharaj, Wu, C. P. Hornik, Balevic.
Obtained funding: Benjamin, Cohen-Wolkowiez.
Administrative, technical, or material support: C. D. Hornik, Cohen-Wolkowiez.
Supervision: C. P. Hornik, Benjamin, Cohen-Wolkowiez.
Conflict of Interest Disclosures: Dr C. P. Hornik reported personal fees from Anavex Pharmaceuticals and grants from Pfizer outside the submitted work. Dr Balevic reported grants, nonfinancial support, and other support from the US Food and Drug Administration, grants from the National Institutes of Health, Patient-Centered Outcomes Research Institute, Rheumatology Research Foundation, Thrasher Research Fund, and Childhood Arthritis and Research Alliance/Arthritis Foundation; and personal fees from UCB outside the submitted work. Dr Gonzalez reported a travel grant through the University of North Carolina at Chapel Hill to give a presentation at Boehringer Ingelheim outside the submitted work and support for research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr Zimmerman reported grants from the National Institutes of Health during the conduct of the study. Dr Maharaj receives research support from the Thrasher Research Fund (www.thrasherresearch.org). Dr Smith receives funding from the National Institutes of Health. Dr Benjamin receives support from the National Institutes of Health, National Institute of Child Health and Human Development, the National Center for Advancing Translational Sciences, and Food and Drug Administration and personal fees from Astellas Pharma, Cidara Therapeutics, Allergan, and Lediant outside the submitted work. Dr Cohen-Wolkowiez receives support from the National Institutes of Health, National Institute of Child Health and Human Development, the National Center for Advancing Translational Sciences, and the US Food and Drug Administration; he also receives research support from industry for neonatal and pediatric drug development. No other disclosures were reported.
Funding/Support: This work was funded through support from the National Institutes of Health grant 1K24-AI143971 (Dr Cohen-Wolkowiez). This work was also funded under the National Institute of Child Health and Human Development contract (HHSN275201000003I) for the Pediatric Trials Network (Principal Investigator, Dr Benjamin).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee Members: Daniel K. Benjamin Jr, MD, PhD, MPH, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Christoph P. Hornik, MD, PhD, MPH, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Kanecia O. Zimmerman, MD, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Phyllis Kennel, MS, RD, LDN, PMP, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Rose Beci, BS, Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Chi Dang Hornik, PharmD, Duke University Medical Center, Durham, North Carolina; Gregory L. Kearns, BSc (Pharm), PharmD, PhD, TCU-UNTHSC School of Medicine, Fort Worth, Texas; Matthew Laughon, MD, MPH, University of North Carolina at Chapel Hill; Ian M. Paul, MD, MSc, Penn State College of Medicine, Hershey, Pennsylvania; Janice E. Sullivan, MD: University of Louisville, Louisville, Kentucky; Kelly Wade, MD, PhD, MSCE, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Paula Delmore, MSM, Wichita Medical Research and Education Foundation, Wichita, Kansas; Perdita Taylor-Zapata, MD, The Eunice Kennedy Shriver National Institute of Child Health and Human Development; June Lee, MD, PhD, The Eunice Kennedy Shriver National Institute of Child Health and Human Development. PTN Publications Committee: Chaired by Thomas P. Green, MD, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Disclaimer: All information and materials in the manuscript are original. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Additional Contributions: We thank Erin Campbell, MS, for her editorial assistance. Ms Campbell did not receive compensation for her assistance, apart from her employment at Duke Clinical Research Instititue.
D , Houpikian
P , Tissot Dupont
H , Riss
JM , Arditi-Djiane
J , Brouqui
P . Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch Intern Med
. 1999;159(2):167-173. doi:10.1001/archinte.159.2.167PubMedGoogle ScholarCrossref
X , Ye
F , Zhang
et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis
. 2020:ciaa237. doi:10.1093/cid/ciaa237PubMedGoogle Scholar
HS , Im
JS , Cho
et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob Agents Chemother
. 2009;53(4):1468-1475. doi:10.1128/AAC.00339-08PubMedGoogle ScholarCrossref
ML , Andres
EL , Sims
et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio
. 2018;9(2):e00221-e18. doi:10.1128/mBio.00221-18PubMedGoogle ScholarCrossref
AR , Edginton
AN . Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometrics Syst Pharmacol
. 2014;3:e150. doi:10.1038/psp.2014.45PubMedGoogle Scholar
M , Yang
Y , Zhang
et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration’s Office of Clinical Pharmacology. J Pharm Sci
. 2019;108(1):21-25. doi:10.1016/j.xphs.2018.10.033PubMedGoogle ScholarCrossref
I , Tegenge
MA . A comparative study between allometric scaling and physiologically based pharmacokinetic modeling for the prediction of drug clearance from neonates to adolescents. J Clin Pharmacol
. 2019;59(2):189-197. doi:10.1002/jcph.1310PubMedGoogle ScholarCrossref
H . ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag; 2009.
W , Duvvuri
S , Buckeridge
C . Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn
. 2015;42:S65-S65.Google Scholar
G , Zeileis
A . zoo: S3 infrastructure for regular and irregular time series. J Stat Softw
. 2005;14(i06).Google Scholar
HW , Ma
ZX , Chen
J , Yang
XY , Cheng
JL , Li
YB . Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther
. 2015;2(2):183-195. doi:10.1007/s40744-015-0012-0PubMedGoogle ScholarCrossref
XQ , Björkman
A , Andersson
TB , Gustafsson
LL , Masimirembwa
CM . Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol
. 2003;59(5-6):429-442. doi:10.1007/s00228-003-0636-9PubMedGoogle ScholarCrossref
KWK , van Groen
BD , Spaans
et al. A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther
. 2019;106(5):1083-1092. doi:10.1002/cpt.1516PubMedGoogle ScholarCrossref
S , Höhn
K , Edginton
et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn
. 2007;34(3):401-431. doi:10.1007/s10928-007-9053-5PubMedGoogle ScholarCrossref
NI , Krismartina
M , Rico-Rico
A , Blaauboer
BJ , Hermens
JL . Quantifying processes determining the free concentration of phenanthrene in Basal cytotoxicity assays. Chem Res Toxicol
. 2012;25(2):436-445. doi:10.1021/tx200479kPubMedGoogle ScholarCrossref
D , Dai
SM , Tong
Q . COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother
. 2020:dkaa114. doi:10.1093/jac/dkaa114PubMedGoogle Scholar
SLM , Buckner
F . Hydroxychloroquine for treatment of SARS-CoV-2 infection? improving our confidence in a model-based approach to dose selection. Clin Transl Sci
. 2020;. doi:10.1111/cts.12797PubMedGoogle Scholar
JY , Vinayagamoorthy
N , Han
et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol
. 2016;68(1):184-190. doi:10.1002/art.39402PubMedGoogle ScholarCrossref
D , Baune
B , Farinotti
et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos
. 2003;31(6):748-754. doi:10.1124/dmd.31.6.748PubMedGoogle ScholarCrossref